NID2 and HOXA9 Promoter Hypermethylation as Biomarkers for Prevention and Early Detection in Oral Cavity Squamous Cell Carcinoma Tissues and Saliva

Differentially methylated oral squamous cell carcinoma (OSCC) biomarkers, identified in vitro and validated in well-characterized surgical specimens, have shown poor clinical correlation in cohorts with different risk profiles. To overcome this lack of relevance, we used the HumanMethylation27 BeadChip, publicly available methylation and expression array data, and quantitative methylation specific PCR to uncover differential methylation in OSCC clinical samples with heterogeneous risk profiles. A two stage design consisting of discovery and prevalence screens was used to identify differential promoter methylation and deregulated pathways in patients diagnosed with OSCC and head and neck squamous cell carcinoma. Promoter methylation of KIF1A (κ = 0.64), HOXA9 (κ = 0.60), NID2 (κ = 0.60), and EDNRB (κ = 0.60) had a moderate to substantial agreement with clinical diagnosis in the discovery screen. HOXA9 had 68% sensitivity, 100% specificity, and a 0.81 Area Under the Curve (AUC). NID2 had 71% sensitivity, 100% specificity, and a 0.79 AUC. In the prevalence screen, HOXA9 (κ = 0.82) and NID2 (κ = 0.80) had an almost perfect agreement with histologic diagnosis. HOXA9 had 85% sensitivity, 97% specificity, and a 0.95 AUC. NID2 had 87% sensitivity, 95% specificity, and a 0.91 AUC. A HOXA9 and NID2 gene panel had 94% sensitivity, 97% specificity, and a 0.97 AUC. In saliva, from OSCC cases and controls, HOXA9 had 75% sensitivity, 53% specificity, and a 0.75 AUC. NID2 had 87% sensitivity, 21% specificity, and a 0.73 AUC. This phase I Biomarker Development Trial identified a panel of differentially methylated genes in normal and OSCC clinical samples from patients with heterogeneous risk profiles. This panel may be useful for early detection and cancer prevention studies. Cancer Prev Res; 4(7); 1061–72. ©2011 AACR.

[1]  J. Califano,et al.  KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses , 2010, International journal of cancer.

[2]  T. Matsuda,et al.  Comparison of time trends in lip, oral cavity and pharynx cancer mortality (1990-2006) between countries based on the WHO mortality database. , 2010, Japanese journal of clinical oncology.

[3]  C. la Vecchia,et al.  Alcohol consumption and cancers of the oral cavity and pharynx from 1988 to 2009: an update , 2010, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  Zhe Zhang,et al.  Endothelin Receptor Type B Gene Promoter Hypermethylation in Salivary Rinses Is Independently Associated with Risk of Oral Cavity Cancer and Premalignancy , 2010, Cancer Prevention Research.

[5]  A. A. Ocampo Rios,et al.  First measurement of Bose-Einstein correlations in proton-proton collisions at √s=0.9 and 2.36 TeV at the LHC. , 2010, Physical review letters.

[6]  L. de Leval,et al.  Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. , 2010, European urology.

[7]  G. Hon,et al.  Next-generation genomics: an integrative approach , 2010, Nature Reviews Genetics.

[8]  Lee E. Edsall,et al.  Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. , 2010, Cell stem cell.

[9]  M. Benezra,et al.  HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. , 2010, The Journal of clinical investigation.

[10]  David Sidransky,et al.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers. , 2010, Cancer research.

[11]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[12]  A. Ruano-Raviña,et al.  Tobacco consumption and oral and pharyngeal cancer in a Spanish male population. , 2010, Cancer letters.

[13]  A. Zini,et al.  Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[14]  Steven S. Chang,et al.  Integrative Discovery of Epigenetically Derepressed Cancer Testis Antigens in NSCLC , 2009, PloS one.

[15]  J. Herman,et al.  GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer , 2009, Clinical Cancer Research.

[16]  Steven S. Chang,et al.  Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. , 2009, Oral oncology.

[17]  F. Hilgers,et al.  The surgical dilemma of ‘functional inoperability’ in oral and oropharyngeal cancer: current consensus on operability with regard to functional results , 2009, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[18]  S. Warnakulasuriya.  Global epidemiology of oral and oropharyngeal cancer. , 2009, Oral oncology.

[19]  Steven S. Chang,et al.  Coordinated Activation of Candidate Proto-Oncogenes and Cancer Testes Antigens via Promoter Demethylation in Head and Neck Cancer and Lung Cancer , 2009, PloS one.

[20]  Ru-Fang Yeh,et al.  Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. , 2009, Carcinogenesis.

[21]  A. Olshan,et al.  Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. , 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  R. Lothe,et al.  Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers , 2008, Molecular Cancer.

[23]  B. Schmidt,et al.  Methylation Array Analysis of Preoperative and Postoperative Saliva DNA in Oral Cancer Patients , 2008, Cancer Epidemiology Biomarkers & Prevention.

[24]  G. Tonon,et al.  From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. , 2008, Future oncology.

[25]  Stefan Joos,et al.  Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). , 2008, Neoplasia.

[26]  Guojun Wu,et al.  Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer , 2008, The Prostate.

[27]  Steven S. Chang,et al.  Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma , 2008, Clinical Cancer Research.

[28]  Yingye Zheng,et al.  Integrating the predictiveness of a marker with its performance as a classifier. , 2007, American journal of epidemiology.

[29]  Jiajie Zhang,et al.  MethyCancer: the database of human DNA methylation and cancer , 2007, Nucleic Acids Res..

[30]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[31]  Hsuan-Cheng Huang,et al.  MeInfoText: associated gene methylation and cancer information from text mining , 2008, BMC Bioinformatics.

[32]  J. Califano,et al.  DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage , 2007, International journal of cancer.

[33]  S. Belinsky,et al.  Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. , 2007, Cancer research.

[34]  Takako Sasaki,et al.  Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer , 2007, Molecular Cancer.

[35]  E. Brambilla,et al.  Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence , 2007, Clinical Cancer Research.

[36]  S. Srivastava.  Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach. , 2007, Gastrointestinal cancer research : GCR.

[37]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[38]  R. Shaw.  The epigenetics of oral cancer. , 2006, International journal of oral and maxillofacial surgery.

[39]  Joseph A Califano,et al.  Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. , 2006, The Lancet. Oncology.

[40]  A. Neugut,et al.  Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  M. Perucho,et al.  Genetics supersedes epigenetics in colon cancer phenotype. , 2003, Cancer cell.

[42]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[44]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[45]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[46]  V. Domínguez-Rojas,et al.  Risk of oral cancer associated with tobacco smoking, alcohol consumption and oral hygiene: a case-control study in Madrid, Spain. , 2000, Oral oncology.